Back to Results
First PageMeta Content



Daiichi Sankyo Signs Agreement with Translational Sciences, Inc. to Develop and Commercialize the First-In-Class Thrombus Dissolving Agent, TS23 TOKYO, Japan (September 15, 2015) – Daiichi Sankyo Company, Ltd. (hereaft
Add to Reading List

Document Date: 2016-01-03 23:45:25


Open Document

File Size: 84,05 KB

Share Result on Facebook
UPDATE